Lantern Pharma Inc. (LTRN) News
Filter LTRN News Items
LTRN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LTRN News Highlights
- LTRN's 30 day story count now stands at 2.
- Over the past 13 days, the trend for LTRN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG, HGBL and ODD are the most mentioned tickers in articles about LTRN.
Latest LTRN News From Around the Web
Below are the latest news stories about LANTERN PHARMA INC that investors may wish to consider to help them evaluate LTRN as an investment opportunity.
The 3 Most Undervalued AI Penny Stocks to Buy in DecemberIt’s easy to understand why investors remain curious about AI penny stocks in December and beyond. Leading companies in the artificial intelligence (AI) industry have multiplied in value in 2023. The AI market was worth roughly $515 billion in 2023. By 2030, it is expected to more than quadruple in value, reaching $2.025 trillion. That equates to a compound annual growth rate of more than 21% over the period. So, it’s easy to see why investors are scrambling to invest in undervalued penny in the |
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)DALLAS, November 30, 2023--FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL). This is the second ODD for LP-284. |
Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call TranscriptLantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Good afternoon, and welcome to our Third Quarter 2023 Earnings Call. As a reminder, this call is being recorded and all attendees are in a listen-only mode. We will open the call for questions and answers after our management’s presentation. A webcast […] |
LTRN: Three Assets in the Clinic in 3Q:23By John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Third Quarter 2023 Financial and Operational Results On November 8, 2023, Lantern Pharma, Inc. (NASDAQ:LTRN) announced 3Q:23 financial and operational results, filed its Form 10-Q with the SEC and hosted a video webcast to review accomplishments. Since Lantern’s second quarter update, it has added new sites in Asia for its |
Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational UpdatesAdvancements in Clinical Trials and AI Platform Highlighted Amid Financial Discipline |
Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational HighlightsDALLAS, November 08, 2023--Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights |
Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ETDALLAS, November 01, 2023--'Save the date" for Q3-2023 LTRN Earnings Call |
The 7 Most Undervalued AI Penny Stocks to Buy: October 2023Unlock exponential growth with the next big undervalued AI penny stocks to buy, offering tremendous upside ahead. |
Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ETDALLAS, October 10, 2023--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that Lantern management will be presenting at the ThinkEquity Conference on Thursday, October 19, 2023, at the Mandarin Oriental in New York, NY. |
Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in GlioblastomaDALLAS, October 03, 2023--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine learning (ML) platform, RADR®, with multiple clinical stage drug programs, today announced that in vivo data highlighting the enhanced efficacy of Lantern’s drug candidate LP-184 in glioblastoma (GBM) were published in Clinical Cancer Research, a journal of the American Association for Cancer Research. L |